Government Grants for Clinical Research

National Medical Research Council (NMRC)

The NMRC was established in 1994 to oversee research funding from the Singapore Ministry of Health (MOH) and support the development and advancement of biomedical research in Singapore, particularly in the public healthcare clusters and medical schools. NMRC engages in research strategy and planning, provides funding to support competitive research grants and core research enablers, and is responsible for the development of clinician scientists through awards and fellowships. The council’s work is supported by the NMRC Office which is part of MOH Holdings Pte Ltd. Through its management of the various funding initiatives, NMRC promotes healthcare research in Singapore, for better health and economic outcomes.

NMRC grant schemes which support clinicians to carry out clinical trials for the development of novel therapies, interventions and diagnostics, focusing on healthcare needs: 

Competitive Research Grants

  1. CS New Investigator Grant (CS-NIG)

    Subcategory of the CS-IRG for new clinical investigators establishing themselves as independent PIs.Up to 
  • S$270,400 (inclusive of up to 30% indirect costs^) for up to 3 years
  • Grant Call: 01 Jul 2026 - 03 Aug 2026 (Current)
  • 2 grant calls per year (Jan & Jul) 

  • 2. CS Individual Research Grant (CS - IRG)

    Supports clinician scientists in carrying out internationally competitive medical research, including investigator-initiated clinical trials focused on developing novel therapies, interventions, and diagnostics to address healthcare needs. The CS-IRG supports basic, clinical, and translational research.

    • S$2.028M per project (inclusive of up to 30% indirect costs^) for up to 5 years
    • Grant Call: 01 Jul 2026 - 03 Aug 2026 (Current)
    • 2 grant calls per year (Jan & Jul)


    Talent Development 

    1. NMRC Research Training Fellowship (RTF) 

    To outstanding and talented clinicians and health science/healthcare professionals for research training to have qualifications and skills to become clinician scientists/innovators. Priority will be given to talent who are at a relatively early stage of their research career.

    • Local: Up to S$550k per awardee for up to 2 year
    • Overseas: Up to S$330K per awardee for up to 2 years. Institutions are encouraged to co-fund the overseas training if required.
    • Maintenance allowance  and related expenses (e.g. return air travel, health insurance) are in accordance with the institution's guidelines - Unde OOE vote 
    • Overseas conference support of up to S$6,000 per year, applicable only if the awardee is a speaker or poster presenter on a topic relevant to the research project - Under OT vote
    • Research seed funding of up to $30K for 2 years, applicable upon completion of training. Subject to NMRC’s prevailing eligibility criteria and approva
    • Grant Call: 01 Jul 2026 - 03 Aug 2026 (Current)


    2. Clinician Scientist Award (CSA) and Senior CSA 

    Support outstanding clinician scientists (CS) to carry out internationally competitive translational and clinical research, bringing bench discoveries to bedside applications.

    Clinician Scientist Award (CSA) Category

  • Open for clinician scientist with good track records of research work and demonstrated potential to become leaders in this field
  • Award is renewable once under this category
  • S$1.11M direct costs, with up to 30% indirect costs^ and
  • between 0.5 FTE to 0.7 FTE salary support for protected time in research over 5 years.
  • Nominate a mentor at the point of application
  • Grant Call: 01 Jul 2026 - 03 Aug 2026 (Current)

  • Clinician Scientist Award (CSA) - Senior Investigator (SI) Category

  • Open for senior clinician scientist who has demonstrated sustained, high levels of productivity and leadership in this field
  • No limit to the number of renewals.
  • S$1.75M direct costs, with up to 30% indirect costs^ and
  • between 0.5 FTE to 0.7 FTE salary support for protected time in research over 5 years.
  • Expected to mentor junior clinician scientists
  • Grant Call: 01 Jul 2026 - 03 Aug 2026 (Current)

  • 3. Clinician Innovator Award (CIA) and Senior CIA

    Support outstanding clinician scientists (CS) to carry out internationally competitive translational and clinical research, bringing bench discoveries to bedside applications.

    Clinician Innovator Award (CIA) Category

  • Award is renewable once, with a second renewal considered on a case-by-case basis
  • S$265,000 direct costs, with up to 30% indirect costs^ and
  • up to 0.5 FTE salary support for protected time in research over 3 years.
  • Grant Call: 01 Jul 2026 - 03 Aug 2026 (Current)
  • Senior Clinician Innovator Award (CIA) Category

  • No limit to the number of renewals.
  • S$525,000 direct costs, with up to 30% indirect costs^ and
  • up to 0.5 FTE salary support for protected time in research over 3 years.
  • Grant Call: 01 Jul 2026 - 03 Aug 2026 (Current)

  • ^ Indirect costs is not applicable for research scholarship budget.

    For more information about other research funding available, please refer to NMRC Grants.


    National Health Innovation Centre Singapore (NHIC)

    The National Health Innovation Centre Singapore (NHIC) is a nationally appointed programme office that works with Public Health Institutions across Singapore to identify and commercialise promising clinical innovations. NHIC funds the translation and development of medical innovations towards a market-ready product, and provides strategic guidance and connection to industry partners, accelerating the pathway to impact in healthcare.

    For more information about the funding schemes, please refer to NHIC funding.


    Agency for Science, Technology and Research (A*STAR)

    A*STAR is Singapore’s lead public sector agency that spearheads economic-oriented research to advance scientific discovery and develop innovative technology. At A*STAR, the biomedical sciences and physical sciences and engineering research institutes drive impactful research making advancements in basic science, to patented inventions, and ready-to-use technologies. The facilities are centred around Biopolis and Fusionopolis, the adjacent twin research campuses that focus on biomedical and physical & engineering sciences.

    One of the grant schemes which aims to boost the quality and quantity of drug development and biotech pipelines in Singapore would be Singapore Therapeutics Development Review (STDR):

    • In partnership with our strategic partners, the Experimental Drug Development Centre (EDDC), Singapore-MIT Alliance for Research and Technology (SMART) and National Health Innovation Centre (NHIC)
    • 2 grant calls each year, typically in Q1 and Q3.
      • - Pre-Pilot: Up to S$325K per project, inclusive of 30% indirect costs for up to 1 year.
      • - Pilot: Phase 1 funding up to S$400K per project inclusive of 30% indirect for up to 1 year
      • - Pilot: Phase 2 funding up to S$600K per project inclusive of 30% indirect for up to 1 year
    For more information about other research funding available in A*STAR, please refer to Funding Opportunities